Form 4: Artiva Biotherapeutics Director, Alison Moore, Acquires 27,500 Shares Through Stock Option Grant

Alison Moore, a director at Artiva Biotherapeutics, acquired 27,500 shares via a stock option grant on October 21, 2024.

Summary

• On October 21, 2024, Alison Moore, a director of Artiva Biotherapeutics, Inc. (ARTV), was granted a stock option to purchase 27,500 shares of common stock.
• The exercise price of the stock option is $10.48 per share.
• The options vest over a three-year period, with one-third vesting immediately and the remainder vesting monthly over the subsequent two years.
• The stock options expire on October 20, 2034.
• Following the transaction, Ms. Moore directly owns 27,500 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard stock option grant, which is generally viewed positively as it aligns director interests with shareholders. There are no overtly negative aspects presented.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one-third immediately and the remainder monthly over two years is a fairly typical vesting arrangement.
• The exercise price is set at $10.48.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates